CN Patent

CN104017062A — 酰化的glp-1化合物

Assigned to Novo Nordisk AS · Expires 2014-09-03 · 12y expired

What this patent protects

本发明涉及在相对于序列GLP-1(7-37)(SEQ ID No1)的位置7和/或8上具有至少一种非蛋白质源性氨基酸残基修饰的新的长效GLP-1化合物及其治疗用途。

USPTO Abstract

本发明涉及在相对于序列GLP-1(7-37)(SEQ ID No1)的位置7和/或8上具有至少一种非蛋白质源性氨基酸残基修饰的新的长效GLP-1化合物及其治疗用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN104017062A
Jurisdiction
CN
Classification
—
Expires
2014-09-03
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.